Login to Your Account

Financings Roundup

Arrowhead Bolsters Balance Sheet, Adds $36M for Pipeline

By Jennifer Boggs
Managing Editor

Tuesday, May 7, 2013
In the wake of promising preclinical data for its hepatitis B virus (HBV) candidate, Arrowhead Research Corp. shored up its balance sheet in a $36 million private offering to advance pipeline work, including planned clinical trials of ARC-520, an RNAi-based drug in chronic HBV infection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription